ONCOLOGY Vol 36, Issue 3

Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.

Shilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.

Dr. Judd W. Moul, MD, and colleagues present the case of a man, aged 73 years, with a prostate-specific antigen level of 110 ng/mL after 4 negative prostate biopsies and 4 negative prostate MRIs.

In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.

“Team science is important for being open-minded [and] thinking outside of the box.”

In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.